首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1543637

生物技術許可交易（2019-2024）

Licensing Deals in Biotechnology 2019-2024

出版日期: 2024年09月01日 | 出版商:

Current Partnering | 英文 1250+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

本報告深入了解和分析公司如何以及為何進行許可交易。

本報告提供了2019年至2024年許可交易的詳細資訊。

透過本報告可以了解雙方宣布的授權交易的付款條款。這些資料提供了有關支付條款和其他交易條款的寶貴見解。

了解潛在合作夥伴談判條款的彈性，並深入了解談判過程，以了解條款談判期間的預期結果。許多小型企業會要求提供付款條件的詳細信息，但在包括付款方式和權利如何轉讓時，細節是關鍵。

本報告提供了自2019年以來宣布的許可交易，全面列出目前協議案件/合作夥伴資料庫中記錄的內容，並包括可用的財務條款，以及公司及其合作夥伴向證券交易委員會提交的實際許可協議文件的線上副本的連結。

主要優點

本報告為讀者提供了以下主要好處：

了解2019年以來的交易完成趨勢
查看許可交易
基準分析：確定交易的市場價值
財務狀況
交易清單：依公司名稱（A-Z）、依治療領域、依技術類型
主要交易（金額基礎）
最活躍的交易者
每筆交易的資產識別和交易條件
取得合約文件：深入了解交易結構
實質審查：評估擬議交易條款對合作夥伴公司的適用性
節省數百小時的研究時間

調查範圍

本報告目的是詳細了解全球領先生物製藥公司的許可趨勢和交易結構。

此報告包含以下資訊：

生物製藥產業許可交易的趨勢
許可交易結構：概述
整個生技產業的許可證交易記錄列表
主要許可交易（價值基礎）
最活躍的許可貿易夥伴
用於授權交易的主要合作夥伴資源

此報告列出了可獲得資訊的交易：

依公司名稱（A-Z）
依交易金額
依治療領域
依技術型
每個交易標題都透過網路連結連結到實際交易記錄的線上版本。
此報告提供了對許可協議的可用合約文件的全面存取。

透過分析合約協議，實質審查可以：

授予和選擇了哪些權利？
合約授予了哪些權利？
授予哪些專有權？
合約的付款結構是怎樣的？
如何審核銷售和付款？
合約期限是多久？
合約的主要條款是如何定義的？
如何對待和擁有知識產權？
誰負責商業化？
誰負責開發、供應和製造？
如何管理保密和發布？
如何解決爭議？
什麼情況下可以取消合約？
如果所有者發生變化會怎樣？
已商定何種類型的分授權或分包條款？
公司需要哪些樣板條款？
哪些樣板條款會根據合作夥伴和交易類型的不同而有所不同？
每家公司都主張合約法中的哪一個管轄權？

簡介
許可交易的定義
授權交易趨勢（2019年後）
- 締結許可交易：依年份（2019-2024年）
- 締結許可交易：依開發階段劃分（2019-2024年）
- 締結許可交易：依行業分類（2019-2024年）
- 締結許可交易：依治療領域劃分（2019-2024年）
- 締結許可交易：依技術類型劃分（2019-2024年）
- 締結許可交易：針對最活躍的公司（2019-2024年）
簽訂許可交易協議的原因
未來的授權交易

第3章許可交易結構：概述

簡介
許可交易的結構

第4章主要許可交易

簡介
主要許可交易（價值基礎）

第5章最活躍的25家許可證貿易公司

簡介
前 25 位最活躍的授權交易合作夥伴（達成交易的公司）

第6章許可交易清單（包括合約詳細資料）

簡介
授權交易協議（2019-2024）
交易列表
交易清單：締結許可交易，依公司名稱（A-Z）
交易清單：締結許可交易，依治療領域
交易清單：締結許可交易，依技術類型

關於Wildwood Ventures

目前的合作關係
當前合約
Current Partnering 發布的最新報告標題

簡介目錄

Product Code: CP2063b

Licensing Deals in Biotechnology provides a detailed understanding and analysis of how and why companies enter licensing deals.

Fully revised and updated, the report provides details of licensing deals from 2019 to 2024.

The report provides access to licensing deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of licensing dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in licensing as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of licensing deals.

Chapter 4 provides a review of the leading licensing deals since 2019. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active licensing dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 6 provides a comprehensive and detailed review of licensing deals organized by company A-Z, therapy, technology and industry type signed and announced since 2019 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the licensing deal.

The deal directory includes a comprehensive listing of all licensing deals announced since 2019. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in licensing dealmaking since 2019.

In conclusion, this report provides everything a prospective dealmaker needs to know about licensing alliances.

Key benefits

Licensing Deals in Biotechnology provides the reader with the following key benefits:

Understand deal trends since 2019
Browse licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, therapy focus and technology type
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Report scope

Licensing Deals in Biotechnology is intended to provide the reader with an in-depth understanding of the licensing trends and structure of deals entered into by leading biopharma companies worldwide.

Licensing Deals in Biotechnology includes:

Trends in licensing dealmaking in the biopharma industry
Overview of licensing deal structure
Directory of licensing deal records covering pharmaceutical and biotechnology
The leading licensing deals by value
Most active licensing dealmakers
The leading licensing partnering resources

In Licensing Deals in Biotechnology, the available deals are listed by:

Company A-Z
Headline value
Therapeutic area
Technology type
Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
Licensing Deals in Biotechnology provides comprehensive access to available records for licensing deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the rights granted or optioned?
What rights are granted by the agreement?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are intellectual property rights handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in licensing dealmaking

2.1. Introduction
2.2. Definition of licensing deal
2.3. Trends in licensing deals since 2019
- 2.3.1. Licensing dealmaking by year, 2019-2024
- 2.3.2. Licensing dealmaking by phase of development, 2019-2024
- 2.3.3. Licensing dealmaking by industry sector, 2019-2024
- 2.3.4. Licensing dealmaking by therapy area, 2019-2024
- 2.3.5. Licensing dealmaking by technology type, 2019-2024
- 2.3.6. Licensing dealmaking by most active company, 2019-2024
2.4. Reasons for entering into licensing partnering deals
2.5. The future of licensing deals